Get the Stockscreener App
8.836
3.43%
-0.314
After Hours:
8.82
-0.016
-0.18%
Karyopharm Therapeutics Inc stock is traded at $8.836, with a volume of 509.39K.
It is down -3.43% in the last 24 hours and up +45.09% over the past month.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
See More
Previous Close:
$9.15
Open:
$9.13
24h Volume:
509.39K
Relative Volume:
1.08
Market Cap:
$162.09M
Revenue:
$137.27M
Net Income/Loss:
$-123.57M
P/E Ratio:
-0.8021
EPS:
-11.016
Net Cash Flow:
$-102.89M
1W Performance:
-5.50%
1M Performance:
+45.09%
6M Performance:
+33.88%
1Y Performance:
+44.38%
1-Day Range:
$8.68
$9.17
1-Week Range:
$8.68
$9.831
52-Week Range:
$3.51
$10.99
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Name
Karyopharm Therapeutics Inc
Sector
Industry
Phone
617-658-0600
Address
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
8.836 | 167.85M | 137.27M | -123.57M | -102.89M | -11.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-26 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-13-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-16-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-19-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-09-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-06-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-02-20 | Initiated | Morgan Stanley | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-23-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-05-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-05-19 | Reiterated | Robert W. Baird | Outperform |
| Mar-01-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-28-19 | Reiterated | BofA/Merrill | Underperform |
| Feb-27-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-03-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-03-18 | Initiated | B. Riley FBR | Buy |
| Nov-09-18 | Upgrade | Wedbush | Neutral → Outperform |
| May-24-18 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-02-18 | Resumed | Leerink Partners | Outperform |
| Nov-15-17 | Resumed | H.C. Wainwright | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-08-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Upgrade | Jefferies | Hold → Buy |
| Aug-18-16 | Initiated | H.C. Wainwright | Buy |
| Jun-28-16 | Initiated | Robert W. Baird | Outperform |
View All
Karyopharm Therapeutics Inc Stock (KPTI) Latest News
Tax-driven share sale by Karyopharm (KPTI) EVP Mano Michael disclosed - Stock Titan
Karyopharm (NASDAQ: KPTI) EVP sells shares for tax withholding - Stock Titan
Karyopharm (KPTI) EVP executes automatic share sale for tax withholding - Stock Titan
Karyopharm (KPTI) CEO executes automatic 12,361-share sale to cover RSU taxes - Stock Titan
Automatic tax-sale trims Karyopharm (NASDAQ: KPTI) EVP shareholdings - Stock Titan
Karyopharm Therapeutics Inc. 8-K Filing and Material Definitive Agreement (February 27, 2026) - Minichart
KPTI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Karyopharm Therapeutics Incon February 27, 2026, company enters second amendment to Credit AgreementSEC filing - marketscreener.com
Karyopharm Amends Credit Agreement to Extend Liquidity Runway - TipRanks
According to a filing submitted to the U.S. Securities and Exchange Commission (SEC), Karyopharm Therapeutics Inc. has obtained permission through an amended agreement to defer the payment deadline for certain amounts until September 2026. - Bitget
Karyopharm Therapeutics Amends Credit Agreement to Defer 2026 Payments, Tied to $25M Equity Raise - TradingView
[Form 4] Karyopharm Therapeutics Inc. Insider Trading Activity - Stock Titan
Karyopharm (KPTI) debt relief and forbearance depend on $25M stock sale - Stock Titan
Karyopharm Grants 1,450 RSUs to New Hires - National Today
Pharma company Karyopharm gives 1,450 stock units to two new hires - Stock Titan
Karyopharm (KPTI) Q4 2025 Earnings Call Transcript - AOL.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Sees Significant Increase in Short Interest - MarketBeat
Karyopharm Therapeutics Target of Unusually Large Options Trading (NASDAQ:KPTI) - MarketBeat
KPTI Should I Buy - Intellectia AI
Karyopharm Therapeutics Shareholders Approve Plan to Nearly Double Authorized Shares at Special Meeting - Yahoo Finance
Earnings call transcript: Karyopharm sees 11.8% revenue rise in Q4 2025 - Investing.com Nigeria
New Highs: Should I set a stop loss on NVAXEarnings Growth Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
HC Wainwright Brokers Lift Earnings Estimates for KPTI - MarketBeat
Can Karyopharm Therapeutics Inc. disrupt its industryJuly 2025 Price Swings & Stepwise Trade Signal Guides - mfd.ru
Karyopharm Shareholders Approve Major Authorized Share Increase - TipRanks
KPTI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Wall Street Analysts Believe Karyopharm Therapeutics (KPTI) Could Rally 56.06%: Here's is How to Trade - Zacks Investment Research
HC Wainwright Reaffirms "Buy" Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
KPTI Receives Reiterated "Buy" Rating from HC Wainwright & Co. | - GuruFocus
Registration Momentum Builds Across the Oncology Pipeline - GlobeNewswire
T. Rowe Price reports 11.8% Karyopharm Therapeutics (KPTI) stake - Stock Titan
Aug Movers: Can Karyopharm Therapeutics Inc disrupt its industry2025 Retail Activity & Low Drawdown Momentum Ideas - baoquankhu1.vn
Analyst Estimates: Here's What Brokers Think Of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) After Its Full-Year Report - 富途牛牛
Analysts Have Made A Financial Statement On Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Annual Report - Yahoo Finance
Karyopharm Earnings Call: Pivotal Data Amid Cash Squeeze - The Globe and Mail
Is Karyopharm Therapeutics Inc.’s growth already priced in2025 Market Outlook & Daily Profit Focused Stock Screening - mfd.ru
Karyopharm Therapeutics Faces Rising Regulatory and Political Risks Amid Supreme Court Limits on FDA Authority - TipRanks
Karyopharm Therapeutics to Announce Q4 Earnings on February 12 - Intellectia AI
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2025 Earnings Call Transcript - Insider Monkey
Karyopharm Therapeutics Inc. SEC 10-K Report - TradingView
Karyopharm Q4 2025 slides: Revenue growth amid pivotal myelofibrosis readout preparations - Investing.com Australia
Karyopharm Therapeutics Inc Shares Rise After Q4 2025 Results - AlphaStreet News
Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst ... By GuruFocus - Investing.com Canada
Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlig - GuruFocus
Karyopharm Therapeutics Q4 Earnings Call Highlights - MarketBeat
Karyopharm reports fourth quarter and full year 2025 financial results and highlights recent company progress - marketscreener.com
Karyopharm Therapeutics (NASDAQ:KPTI) Releases Earnings Results - MarketBeat
Page not foundAirwhon - MarketBeat
KPTI: Q4 revenue up, operating loss improved, pivotal phase 3 data in myelofibrosis due soon - TradingView
Karyopharm Therapeutics Inc Stock (KPTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):